<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909723</url>
  </required_header>
  <id_info>
    <org_study_id>NOV-001-CL01</org_study_id>
    <nct_id>NCT04909723</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects</brief_title>
  <official_title>Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novome Biotechnologies Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novome Biotechnologies Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first stage of this study is a prospective, adaptive, Phase 1, first-in-human,&#xD;
      randomized, controlled study evaluating safety, tolerability, and pharmacodynamics of NOV-001&#xD;
      in adult healthy volunteers.&#xD;
&#xD;
      The second stage of this study is a prospective, randomized, single-blinded,&#xD;
      placebo-controlled study of safety, tolerability, and early efficacy in patients with enteric&#xD;
      hyperoxaluria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is evaluating the safety, tolerability, pharmacodynamics, and early efficacy of&#xD;
      NOV-001. NOV-001 is an investigational combination product composed of NB1000S, a recombinant&#xD;
      live biotherapeutic product, and NB2000P, a botanically derived polysaccharide. NB1000S is&#xD;
      anticipated to be administered once on the first day of treatment (or potentially more than&#xD;
      once daily over the first days of treatment) and NB2000P is administered one or more times&#xD;
      daily for 14 days at variable doses as determined Stage 1 of this adaptive study design. In&#xD;
      Stage 2, NB1000S (or placebo) is anticipated to be administered one or more times per day on&#xD;
      the first and potentially subsequent days of the treatment period and NB2000P (or placebo) is&#xD;
      administered one or more times daily for 28 days, at doses determined in Stage 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</measure>
    <time_frame>Up to 182 days</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>NB1000S engraftment as measured by quantitative Polymerase Chain Reaction (qPCR) determination of concentration of NB1000S strain genomic copies (cells/mL) in stool, change from baseline.</measure>
    <time_frame>Up to 182 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The proportion of subjects with NB100S strain abundance in stool, as measured by qPCR determination of concentration of strain genomic copies (cells/mL).</measure>
    <time_frame>Up to 182 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to strain engraftment, based on the time to reach NB1000S strain abundance by qPCR determination of concentration of NB1000S strain genomic copies (cells/mL).</measure>
    <time_frame>Up to 182 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fecal shedding of NB1000S strain as measured by qPCR determination of concentration of NB1000S strain genomic copies (cells/mL), during treatment and follow-up periods.</measure>
    <time_frame>Up to 182 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Absolute change from baseline in 24-hour urinary oxalate (UOx) excretion (mg/mL), NOV-001 compared to placebo.</measure>
    <time_frame>Stage 2; 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent change from baseline in 24-hour UOx excretion (mg/mL), NOV-001 compared to placebo.</measure>
    <time_frame>Stage 2; 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients achieving â‰¥ 20% reduction in 24-hour UOx excretion from baseline to end of treatment, NOV-001 compared to placebo.</measure>
    <time_frame>Stage 2; 28 days</time_frame>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Enteric Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Stage 1 placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 NB1000S 10^9 CFU one time on Day 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 0.5g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 10g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(Optional) Stage 1 variable doses of NB1000S and NB2000P at varying dosing regimens.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive trial design supports the enrollment of additional arms with variable doses of NB1000S, NB2000P, at varying frequencies of NB1000S and NB2000P administrations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 NB2000P at a dose to be determined</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 NOV-001 at dose determined in Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive NOV-001 (consisting of NB1000S and NB2000P at a dose and regimen determined in Stage 1) for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive placebo for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>NOV-001</intervention_name>
    <description>NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.</description>
    <arm_group_label>(Optional) Stage 1 variable doses of NB1000S and NB2000P at varying dosing regimens.</arm_group_label>
    <arm_group_label>Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 0.5g/day</arm_group_label>
    <arm_group_label>Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 10g/day</arm_group_label>
    <arm_group_label>Stage 2 NOV-001 at dose determined in Stage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NB1000S</intervention_name>
    <description>A recombinant live biotherapeutic product.</description>
    <arm_group_label>Stage 1 NB1000S 10^9 CFU one time on Day 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NB2000P</intervention_name>
    <description>A botanically derived polysaccharide.</description>
    <arm_group_label>Stage 1 NB2000P at a dose to be determined</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Stage 1 placebo arm</arm_group_label>
    <arm_group_label>Stage 2 placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Stage 1 Key Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18 to 55&#xD;
&#xD;
          -  Body mass index (BMI) &lt; 38 kg/m2.&#xD;
&#xD;
          -  Healthy as defined by no clinically relevant abnormalities being identified by a&#xD;
             detailed medical history, physical examination, and clinical laboratory tests.&#xD;
&#xD;
          -  If woman of child-bearing potential, must not be pregnant, and must also agree to use&#xD;
             an appropriate highly-effective contraceptive.&#xD;
&#xD;
          -  Willing and able to comply with all study requirements, including duration of stay at&#xD;
             inpatient unit, dietary restrictions, daily study product administration, pregnancy&#xD;
             testing and contraception (if applicable), stool collections, and blood and urine&#xD;
             collections.&#xD;
&#xD;
        Stage 1 Key Exclusion Criteria:&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 80 mL/min/1.73 m2 at Screening.&#xD;
&#xD;
          -  Oral or parenteral antibiotics within 4 weeks prior to Screening, or anticipation of&#xD;
             the need for such antibiotics during the Screening or treatment periods of the study.&#xD;
&#xD;
          -  Current or history of any clinically significant medical illness or disorder the&#xD;
             Investigator considers should exclude the subject from the study.&#xD;
&#xD;
          -  Participation in any investigational intervention study within 30 days prior to study&#xD;
             product administration in this study.&#xD;
&#xD;
          -  Known hypersensitivity to omeprazole.&#xD;
&#xD;
          -  Applicable only to certain study groups depending on emerging Stage 1 data: no current&#xD;
             or anticipated use during the screening or treatment periods of the study of&#xD;
             medications that have the potential for drug-drug interactions (DDI) with omeprazole.&#xD;
&#xD;
        Stage 2 Key Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18 to 65.&#xD;
&#xD;
          -  Hyperoxaluria secondary to Roux-en-Y gastric bypass surgery.&#xD;
&#xD;
          -  24-Hour urinary oxalate (UOx) â‰¥ 60 mg.&#xD;
&#xD;
          -  If woman of child-bearing potential, must not be pregnant and must also agree to use&#xD;
             an appropriate highly effective contraceptive method.&#xD;
&#xD;
          -  Must, in the opinion of the Investigator, be in otherwise good health.&#xD;
&#xD;
          -  Willing and able to comply with all study requirements, including dietary&#xD;
             restrictions, daily study product administration, pregnancy testing and contraception&#xD;
             (if applicable), stool collections, and blood and 24-hour urine collections.&#xD;
&#xD;
        Stage 2 Key Exclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease with eGFR &lt; 30 mL/min/1.73 m2 at Screening.&#xD;
&#xD;
          -  Evidence of current acute renal injury or ongoing clinically significant renal&#xD;
             disease.&#xD;
&#xD;
          -  Oral or parenteral antibiotics within 4 weeks prior to Screening, or anticipation of&#xD;
             the need for such antibiotics during the Screening or treatment periods of the study&#xD;
             (topical antibiotics are permissible.)&#xD;
&#xD;
          -  Taking during the study any treatment for hyperoxaluria except for NOV-001, other than&#xD;
             stable treatments for the management of kidney stones.&#xD;
&#xD;
          -  Taking Vitamin C â‰¥ 300 mg/day for &gt; 10 days within 7 days prior to Screening;&#xD;
             unwilling or unable to discontinue and/or avoid Vitamin C supplementation for the&#xD;
             duration of study product treatment.&#xD;
&#xD;
          -  Known active autoimmune disorder or other condition requiring high dose of systemic&#xD;
             corticosteroids (i.e., &gt; 10 mg/day prednisone or equivalent) or other&#xD;
             immunosuppressant therapy.&#xD;
&#xD;
          -  Current or history of any clinically significant medical illness or disorder other&#xD;
             than enteric hyperoxaluria that the Investigator considers should exclude the patient&#xD;
             from the study.&#xD;
&#xD;
          -  Participation in any investigational intervention study within 30 days prior to study&#xD;
             product administration in this study.&#xD;
&#xD;
          -  Known hypersensitivity to omeprazole.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lachy McLean, MB ChB, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novome Biotechnologies Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lachy McLean, MB ChB, PhD</last_name>
    <phone>415-894-0999</phone>
    <email>lmclean@novomebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polina Bukshpun</last_name>
    <email>pbukshpun@novomebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence G Gervasi</last_name>
      <phone>440-340-9010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Smith</last_name>
      <phone>865-305-9100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Enteric hyperoxaluria</keyword>
  <keyword>Kidney stone</keyword>
  <keyword>Roux-en-Y gastric bypass</keyword>
  <keyword>Hyperoxaluria</keyword>
  <keyword>Secondary hyperoxaluria</keyword>
  <keyword>Oxalate</keyword>
  <keyword>Kidney calcification</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

